a16z Capital Management, L.L.C.

Institutional investor · Portfolio as of Q3 2026

Q3 2026 biggest moves
  • SPCXSPCX

    SpaceX

    Added 63%

    now 92% of portfolio

  • BRVEBRVE

    Braveheart Bio

    New listing

    1.0% of portfolio

  • METAMETA

    Meta Platforms

    Cut 90%

    now 0.1% of portfolio

  • LIMELIME

    Neutron

    New listing

    0.4% of portfolio

13 changes in all

Top Holdings24 positions

Checking export access…
Activity:
SPCX

Space Exploration Technologies Corp.

121.8M$18.4B92.4%$163.15-21.68%
2 qtrssince 2026-Q2
Increased
Unranked
NAVN

Navan, Inc.

28.2M$592.3M3.0%$16.94+42.73%
4 qtrssince 2025-Q4
Unchanged
0
BRVE

Braveheart Bio, Inc.

10.2M$206.7M1.0%$20.20+0.94%
1 qtr
New
71
RVMD

Revolution Medicines, Inc.

782,934$160.7M0.8%$28.68+462.06%
12 qtrssince 2023-Q4
Decreased
0
5.6M$87.8M0.4%——
1 qtr
New
50
LIME

Neutron Holdings, Inc.

2.8M$80.3M0.4%$28.17-31.24%
1 qtr
New
50
XYZ

Block, Inc.

1M$74.8M0.4%——
12 qtrssince 2023-Q4
Unchanged
0
SCTX

Scribe Therapeutics Inc.

3.1M$56.7M0.3%$18.41-34.44%
1 qtr
New
50
FIG

Figma, Inc.

2.6M$53.9M0.3%$51.87-69.60%
5 qtrssince 2025-Q3
Decreased
0
MAZE

Maze Therapeutics, Inc.

1.7M$46.3M0.2%$11.01+184.92%
7 qtrssince 2025-Q1
Unchanged
0
STDN

Standard Nuclear, Inc.

2.9M$34.5M0.2%$11.81-31.08%
1 qtr
New
49
GLTO

DAMORA THERAPEUTICS INC

1.2M$26.3M0.1%$25.90-10.35%
3 qtrssince 2026-Q1
Unchanged
0
BIOA

BioAge Labs, Inc.

3.2M$22.9M0.1%$19.78-78.36%
9 qtrssince 2024-Q3
Unchanged
0
ERAS

Erasca, Inc.

1.4M$21M0.1%$2.13+538.97%
12 qtrssince 2023-Q4
Decreased
0
META

Meta Platforms, Inc.

20,951$15.2M0.1%$731.90-23.37%
5 qtrssince 2025-Q3
Decreased
0
RBLX

Roblox Corporation

274,570$11.6M0.1%$54.38-14.09%
2 qtrssince 2026-Q2
Unchanged
0
CAMP

CAMP4 Therapeutics Corporation

2.1M$8.6M0.0%$5.22-27.39%
8 qtrssince 2024-Q4
Unchanged
0
AKTS

Aktis Oncology, Inc.

415,000$8.1M0.0%$17.89-9.73%
3 qtrssince 2026-Q1
Unchanged
0
BTGO

BitGo Holdings, Inc.

666,356$4.9M0.0%$8.23-59.30%
3 qtrssince 2026-Q1
Unchanged
0
NAUT

Nautilus Biotechnology, Inc.

2.7M$3.8M0.0%$2.99-29.10%
12 qtrssince 2023-Q4
Decreased
0
$19.9B
AUM
24
Positions
Q3 2026
Filing
HI rating · 2.5/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2025-Q2$312,909,254-55.3543264722%
2025-Q3$1,394,890,890345.781283925%
2025-Q4$1,579,784,57813.2550645592%
2026-Q1$1,290,612,468-18.3045279734%
2026-Q2$14,214,935,8341001.41008137%
2026-Q3$19,893,100,53139.9450603457%
Activity profile
$ moved · Q3'26
New7%Increased89%Decreased3%Exited<1%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 1.5 years
<1Q25%1-4Q13%1-2Y0%2Y+63%

a16z Capital Management, L.L.C. manages $19.9B across 24 positions as of Q3 2026. Top holdings: SPCX (92.4%), NAVN (3.0%), BRVE (1.0%). Fund DNA: High Conviction Activist. HoldingsIntel Score: 2.5/5.0.

Top holdings by portfolio weight

Total AUM$20B
SPCX92.35%
NAVN2.98%
BRVE1.04%
RVMD0.81%
FREENOME INC0.44%
LIME0.40%
XYZ0.38%
SCTX0.29%
FIG0.27%
MAZE0.23%
Other0.17%

Portfolio allocation by GICS sector

Sectors3
Technology69.41%
Healthcare28.01%
Communication Services2.58%

Behavioral investing profile

Checking access…
High Conviction Activist
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Solid(2.5 / 5.0)
Holdings P&L38
Conviction63
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

No active accumulation streaks detected for this filer.

Streaks require 2+ consecutive quarters of increased positions in the most recent period.

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used